Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China

Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shun Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang and Binghe Xu

Background: Clinical guidelines generally recommend endocrine therapy (ET) as first-line treatment of hormone receptor-positive advanced breast cancer (HR+ ABC) whereas chemotherapy (CT) should be considered in the presence of life-threatening disease or limited clinical benefit after three sequential ET regimens. However, it is unclear if real-world clinical practice is in accordance with the current guidelines. This study was to present the real-world treatment patterns and ET regimens among HR+ ABC patients in China.

Methods: Using data from the Nation-wide Multicenter Retrospective Clinical Epidemiology Study of Female Advanced Breast Cancer in China (ClinicalTrials.gov

ORIGINAL RESEARCH
published: 11 February 2021
doi: 10.3389/fonc.2020.599604
Qualifying patients for phase 1 clinical trials of antisense oligonucleotide ASO treatment of breast cancer identifies: NCT03047889), we investigated the clinicopathological characteristics, clinical profiles, and treatment patterns of HR+ ABC patients from January 2012 to December 2014.

**Results:** A total of 2,342 patients with HR+ ABC were included in this study. Our findings revealed that, in comparisons with those receiving initial CT (n = 1445), patients initiated ET (n = 402) were significantly older, later recurrent after adjuvant treatment, with a lower rate of visceral involvement and a decreasing quantity of metastatic sites. A total of 1,308 patients received palliative ET while only 18.9% patients (n = 247) reached three lines of ET. Among patients completing more than one line of ET, the median treatment duration was 8 months for the first line, 6 months for the second line, and 3 months for the third line for patients receiving ET. In the advanced setting, the choices of palliative ET regimens were diverse, yet aromatase inhibitor (AI) monotherapy was still the overall mainstay of ET; in contrast, patients were less accessible to everolimus plus AI regimen in this population.

**Conclusions:** Less than one quarter of patients initiated palliative ET for HR+ ABC in routine clinical practice. Patients who received multi-lines of ET experienced successive shorter durations following each line of therapy. This real-life data provides a solid overview of ET for HR+ ABC from China, indicating unmet need for treatment options that improve the effectiveness of endocrine therapy.

**Keywords:** advanced breast cancer, endocrine treatment, epidemiological study, hormone receptor-positive, nationwide survey

**INTRODUCTION**

Breast cancer (BC) has become a major concern of public health among Chinese women over the past decades (1). With over 360,000 newly diagnosed cases and nearly 100,000 deaths in 2018, breast cancer is the most common malignancy among Chinese women (2). Reportedly, advanced breast cancer (ABC) occurs in approximately 6–10% of newly diagnosed cases, and only 20% of ABC patients are estimated to survive 5 years after its diagnosis (3–6).

Hormone receptor positive (HR+) breast cancer is the most common subtype of BC, accounting for 70% of all breast cancer population (7), in which endocrine therapy (ET) is the mainstay of treatment for the whole course of disease treatment (8). According to the European Society for Medical Oncology clinical guidelines, the National Comprehensive Cancer Network (NCCN) guidelines, minimally toxic ET is the preferred initial option for HR+ ABC patients with the absence of rapid disease progression, symptomatic visceral disease, or suspected endocrine resistance (9, 10).

Evidence-based guidelines have provided some recommendations for optimizing management of HR+ ABC; however, these protocols may not always be consistently followed by physicians in daily practice. Besides, it also depends on disease characteristics, individual inclinations, personal drug responses, and socioeconomic factors (11). The nation-wide epidemiological study is an effective way to gain a better understanding of the treatment pattern of HR+ ABC patients. Previous studies have assessed ET treatment patterns among breast cancer patients in the adjuvant setting in China (12, 13).

However, limited data are available for assessing the use of palliative ET for HR+ ABC patients in routine practice.

In this study, we presented data on realistic treatment patterns in a large, multicenter cohort of patients with HR+ ABC in China. This epidemiological study was to improve the understanding of the current status of ET regimens and the factors that influence palliative ET options in HR+ ABC in China, with the aim of providing evidence for the development of current guidelines and medical policies in addition to giving references to the doctors’ continuing medical education.

**METHODS**

**Study Design and Information Sources**

This study was a nation-wide, multi-center, retrospective, epidemiologic study of ABC from January 01, 2012 to December 31, 2014. A total of 21 hospitals, covering seven geographic regions, were involved in this study, with Cancer Institution and Hospital, Chinese Academy of Medical Sciences (CHCAMS) as the leading center for the overall coordination. This study included pathologically confirmed female ABC inpatients in selected months. In our study, inpatients were defined as patients that were treated in inpatient hospitals, whereas outpatients were patients treated in outpatient cancer care facilities, clinics, and day care hospitals. January and February were excluded from the random selection to reduce the confounding effect of the Spring Festival in China. In each selected month, if inpatient admissions were less than the predetermined numbers in that year, more cases from the
neighboring months were enrolled. This study was approved by the Ethics Committee of CHCAMS. Patient consent for this study was not required as there were no anticipated risks to the enrolled patients. All data included in this analysis was in aggregate, de-identified information.

Data Collection and Quality Control
A questionnaire was designed to obtain demographic information and clinical variables, such as age at diagnosis, geographic region, histology grade, hormone receptor (HR), human epidermal growth factor receptor 2 (HER2) status, and treatment information including breast surgery, adjuvant therapy, targeted therapy, radiation therapy, and palliative systemic treatment.

All of the aforementioned information was extracted from medical charts to the designed case report form (CRF) by trained doctors. Then, data was double-entered into computer-based database (Epidata) by two independent data input clerks. All completed databases were sent to CHCAMS for validation. Inconsistencies between the two databases were reported to the local doctors for revision until the databases were consistent. After that, one of the databases was selected to perform a final assessment with the original medical record, then 5% of the medical charts were sent to CHCAMS for quality control review.

Patient Selection
From the program, we obtained clinical and demographic data on 3,913 ABC patients between 2012 and 2014. The HR and HER2 status were mainly dependent on pathology results in surgery, and patients who had not undergone the surgery included puncture results instead. Study protocols recommended to assess estrogen receptor (ER) and progesterone receptor (PR) status as positive if ≥1% were stained. Any ER or PR positive was regarded as HR positive. When the expression status of primary tumor and metastatic tumor differed, either HR-positive was regarded as HR positive. When the expression status of primary status as positive if ≥1% were stained. Any ER or PR positive was regarded as HR positive. When the expression status of primary tumor and metastatic tumor differed, either HR-positive was regarded as HR positive. When the expression status of primary tumor and metastatic tumor differed, either HR-positive was regarded as HR positive.

Descriptive analyses were used to characterize the clinicopathological status of HR+ ABC patients. Descriptive analyses of the number of lines of palliative ET treatment and the number of ET regimens used were also conducted for the HR-positive patients. These patients were divided into two groups: those whose first treatment after ABC diagnosis was ET and those whose first treatment included CT. Baseline characteristics between patients with initial CT and initial ET were compared using χ2 tests for categorical variables, while t-test for continuous variables with normal distribution and Mann–Whitney U test for abnormally distributed variables. Treatment durations were described using medians and interquartile ranges (IQRs). All analyses were performed using SPSS software (version 22.0). A two-sided P value <0.05 was considered to be statistically significant.

RESULTS
Characteristics of HR+ Advanced Breast Cancer Cohort by Age Groups
The study population for this analysis consisted of 2,342 HR+ ABC patients, with the median age of 49 years (ranging from 21 to 88 years) and a mean age of 48.97 (± 10.08) years. Among the study population, 1,364 (58.2%) patients were diagnosed below 50 years and 978 (41.8%) patients over 50 years. Table 1 summarized the frequency and proportion of some characteristics of these patient groups. There were a series of significant differences among the cohorts of patient samples including PgR status, bone-only metastasis, and visceral metastasis (P < 0.05). It was noticed that younger patients had obviously higher rate of PgR positive (83.2 vs 77.5%, P = 0.002) and bone-only metastasis (28.0 vs 23.5%, P = 0.015) in our study. On the contrary, elder group tended to have visceral metastasis than younger patients (47.0 vs 42.4%, P = 0.028). However, there were no significant differences in histological grade, ER status, HER2 status, metastases-free interval (MFI), brain metastasis, and number of metastatic sites among the two age groups (P > 0.05). As the leading composition of adjuvant treatment, adjuvant ET was applied to 1,882 (80.4%) patients, of which 976 (51.9%) received selective estrogen receptor modulators (SERMs) and 261 (13.9%) received aromatase inhibitors (AIs).

Association Between Disease-Related Factors and First-Line Palliative Treatment Choice
The baseline characteristics of patients according to first-line palliative treatment were summarized in Table 2. From the 1,847 patients treated with palliative systemic therapy, 1,445 patients were treated with initial CT, and 402 patients started initial therapy with ET. The mean age of women treated with first-line ET and CT was 48.3 and 50.5 years, respectively (P < 0.0001). Interestingly, significant geographic differences were detected in the CT choice in which the rate of CT performance was higher in the central and south-west area (P < 0.0001). Patients with risk characteristics, such as disease recurrence within 24 months (P = 0.026), increasing number of metastatic sites (P < 0.0001), and visceral involvement (P < 0.0001), generally received palliative CT more often than ET. When looking at HR+ ABC patients categorized by HER2 status, patients with HER2 negative breast cancer were more likely to receive initial ET compared with HER2 positive patients (23.3 vs 18.7%, P = 0.038) (Supplementary Figure 1). Patients with bone-only metastasis were more likely to receive initial ET compared with patients with visceral metastases, of which 165 (34.0%) patients with bone-only metastases received ET as initial metastatic site, yet
742 (82.9%) of patients with visceral metastases were treated with initial CT (P < 0.0001). Target therapy was administered in 20.7% of patients treated with initial CT compared to 15.1% of patients with initial ET (P = 0.013). Instead, the patients who received the first-line ET had a higher proportion of patients who had previously received adjuvant ET, adjuvant CT, radiotherapy and surgery. There were no statistically significant differences between histological grade (P = 0.16), ER status (P = 0.09), PR status (P = 0.21) and brain metastases (P = 0.305).
Patterns of Treatment
Following ABC diagnosis, among the patients with first-line treatment information complete (N = 1,847), the majority of patients (78.2%) received CT as the first-line treatment, and 21.8% initiated ET (including endocrine monotherapy, and endocrine combined targeted therapy) at the first line (Figure 1A). For patients receiving second-line treatment (N = 1,424), ET took up 44.9% proportion, while CT was still the most common treatment pattern (55.1%) (Figure 1B). However, there was no difference in palliative ET Lines between younger and elder patients (Table 1).

Endocrine Treatment Duration
The majority of patients (n = 1,308) received one line of palliative ET during the study period. Among this part of patients, 46.8% (n = 612) received two lines of palliative ET and 18.9% (n = 247) received three lines of therapy. Overall, patients were treated with an average of 2.50 lines of ET (2.58 lines in patients aged ≤50 years vs 2.39 lines in >50 years groups) during the follow-up period. The median duration on each line of ET among patients was 8 (3–17) months of first line, dropping to 6 (2–12) months of second line, and 3 (2–8) months of third line (Table 3).

Endocrine Regimens
Among patients receiving palliative ET (n = 1,308), AI monotherapy was the most frequent application in the first-line therapy (Table 3), of which 637 patients were treated with AI monotherapy in the first line. According to the age group, AI plus OFS was most commonly used in patients aged ≤50 years in the first line (32.9%), followed by SERM monotherapy (28.1%) (Supplementary Figure 2). In the second and third lines of ET, AI monotherapy remained in the same dominant position both in >50 and ≤50 years groups, with 50.2 and 37.2% of patients accessible, respectively. Patients aged >50 years were more commonly treated with AI monotherapy than the ≤50 years group in all lines of ET. SERM monotherapy was used as first-line therapy in 272 (20.8%) patients, 10.8% in the second line and 14.2% in the third line. A total of 138 patients (10.6% of the total palliative ET population) were treated with fulvestrant. Regarding the entire patients treated with fulvestrant, 45 (32.6%) were treated in the first line, 56 (40.6%) in the second line, and 37 (26.8%) in the third line. As for ovarian function suppression (OFS) combination therapy (including OFS plus AIs or OFS plus SERMs), there were 313 (23.9%) patients who received this regimen in the first line. The proportion of OFS combination therapy fell off in the second and third lines, which was 19.8 and 15.4% respectively. More patients aged ≤50 years received OFS combination treatment than >50 patients (32.3 vs 3.2%). In our study population, a total of 46 (3.5%) patients were treated with everolimus plus AI regimen (Figure 2).

DISCUSSION
This study presented comprehensive information on patient characteristics, initial palliative treatment choice, and ET regimens in routine clinical practice for patients with HR+ ABC in China. Our results clarified that this was a heterogeneous group of patients in terms of treatment administered, and that treatment modalities differed by clinical and demographic variables.

All patients included in our study were ethnically Chinese, of whom the clinicopathological characteristics were significantly

**TABLE 2 | Continued**

| Characteristics | Initial chemotherapy | Initial endocrine therapy | P value |
|-----------------|----------------------|---------------------------|---------|
|                 | (N = 1445) N (%)     | (N = 402) N (%)           |         |
| 2               | 376 (26.3)           | 93 (23.4)                 |         |
| ≥3              | 340 (23.8)           | 60 (15.1)                 |         |
| Unknown         | 17                   | 4                         |         |

ABC, advanced breast cancer; SD, standard deviation; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; MFI, metastases-free interval.

*Chi-square test.
*P values indicate statistical significance.
TABLE 3 | Endocrine therapy regimens and duration time for patients with different treatment line.

| Age at diagnosis ABC | 1st line | 2nd line | 3rd line |
|----------------------|---------|---------|---------|
| Age at diagnosis ABC  | 1st line | 2nd line | 3rd line |
| 50 years ≤ | Age > 50 years | Total | 50 years ≤ | Age > 50 years | Total | 50 years ≤ | Age > 50 years | Total |
| (N = 769) | (N = 539) | (N = 1,308) | (N = 373) | (N = 239) | (N = 612) | (N = 157) | (N = 90) | (N = 247) |
| Regimens N (%) | 215 (28.0) | 422 (54.9) | 637 (48.7) | 155 (41.5) | 152 (63.6) | 307 (50.2) | 56 (35.7) | 36 (40.0) | 92 (37.2) |
| SERMs + OFS | 37 (4.8) | 3 (0.4) | 40 (3.1) | 8 (2.1) | 1 (0.4) | 9 (1.5) | 5 (3.2) | 0 (0) | 5 (2.0) |
| AIs + OFS | 253 (32.9) | 20 (2.6) | 273 (20.9) | 107 (28.7) | 5 (2.4) | 112 (18.3) | 31 (19.7) | 2 (2.2) | 33 (13.4) |
| Fulvestrant ± OFS | 21 (2.7) | 24 (3.1) | 45 (3.4) | 7 (1.9) | 7 (1.3) | 18 (2.9) | 46 (2.5) | 9 (1.7) | 27 (11.0) |
| mTORd + AIs | 0 (0) | 7 (1.3) | 7 (0.5) | 6 (1.6) | 12 (5.0) | 18 (2.9) | 15 (9.6) | 6 (6.7) | 21 (8.5) |
| Others | 37 (4.8) | 9 (1.7) | 46 (3.5) | 28 (7.5) | 14 (8.9) | 47 (7.6) | 14 (8.9) | 15 (16.7) | 29 (11.7) |

Median duration time (IQR) – Months:

- 8 (3–17)
- 6 (2–12)
- 5 (2–9)
- 4 (1–7)

**Notes:**
- SERMs include tamoxifen and toremifene.
- AIs include letrozole, anastrozole and exemestane.
- mTOR include everolimus.
- Others include progestins, OFS monotherapy, combination therapies (SERMs + mTOR, AIs + progestin and fulvestrant + AIs).

An important finding of this large real-life cohort is the high percentage of initial palliative CT. Previous studies have reported a chemotherapeutic delivery in the first line metastatic setting in 24–54% in Europe and America (14, 23–25). However, our study observed that a substantial proportion (78.2%) of patients with HR+ ABC received CT in the first-line setting in China, which was much higher than the percentages of initial CT found in other real-life reports (4, 14, 23–25). Overall, the majority of HR+ ABC patients were not treated with initiated palliative ET, as recommended by the guidelines for patients without the need for immediate tumor reduction (10). It seems that the efficacy of CT is overestimated in real life, and the usage of ET first has not been adopted by a majority of oncologists in China (26).

In this observational study, we found that a group of demographic and clinicopathological features could have an impact on the selection of CT instead of ET as first line palliative treatment. We observed that ET was more extensively used in the elderly compared with younger patients. This tendency fitted in well into other existing studies (14, 24). However, chemotherapy was still a major treatment choice in both younger and older patients. Interestingly, significant geographic differences were detected in the ET choice which was lower in the central and south-west area. The possible explanation for this observation is the disparity of the economic level across the nation. In China, a large proportion of the costs of ET are paid by inpatients and outpatients; thus, patients and physicians’ decisions on whether ET should be used in the first line are affected by the family incomes. Regions such as Northern, Southern, and Eastern China are more economically developed, and people there have higher incomes, and then spend more on health care. Moreover, to achieve the expected efficacy, the patients with history of radiotherapy, surgery, and adjuvant therapy are more inclined to ET in the first line treatment.

We also noted that HER2 status influence the therapeutic decision. Patients with HER2 positive breast cancer were more likely to receive palliative CT compared with HER2 negative patients. Few studies have directly compared ET plus HER2-targeted therapy with CT plus HER2-targeted therapy for HR+ HER2+ ABC patients. The combination of CT and HER2-targeted therapy was shown to present an overall survival (OS) benefit (27), while the treatment based on the combination of ET...
and HER2-targeted therapy was divergent (28). Therefore, CT plus HER2-targeted therapy was strongly recommended for patients with HR-positive and HER2-positive diseases (9, 10). Additionally, our study showed that visceral metastasis and high tumor burden (≥3 organ metastases) were also significant factors for tailoring CT-first treatment. In contrast, when patients presented with bone-only metastasis, the ratio of ET-first (34%) was increased but was still lower than that in European countries (24). In the previous literature, HR+ ABC patients with bone-only metastasis are recognized with a well-defined prognosis (24, 29, 30) and are suggested to undergo ET-first in a series of guidelines (9, 24, 31). These findings fitted in well into existing studies. Lobbezoo et al. (24) observed in their retrospective analysis that a young-onset age at diagnosis and prior adjuvant ET performance exerted a substantial effect on the CT-first decision; and that bone metastasis conversely tend to ET-first approach. Additionally, Watanabe and colleagues (32) reported that patients with visceral involvement, liver metastasis, ≥3 organ involvement, or primary ABC at diagnosis showed a significantly higher tendency to be allocated to the CT-first group.

There were a number of potential reasons for the low use of initial palliative ET observed in our analysis, in which the leading reason is the endocrine resistance. Notably, the majority of HR+ ABC patients (80.4%) in our analysis have received adjuvant ET for early disease. The increased use of endocrine approaches in patients with HR+ tumors in the adjuvant setting, in particular the use of AIs, enables endocrine treatment resistance as a common challenge in HR+ ABC (33, 34). Also, our study indicated that a decreasing proportion of patients with early recurrence (MFI ≤24 months) chose ET in the first line setting compared with those with late recurrence (MFI >24 months). This might be the result of endocrine resistance which tends to occur in early recurrent patients, as recurrent patients who develop endocrine resistance in primary disease are inclined to respond unsatisfactorily to ET and progress to ABC with a decreasing duration. Thus, current recommendations suggest that patients with evidence of ET resistance should be offered CT (9), which may partly account for the extensive use of CT for HR+ ABC.

The NCCN guidelines for ABC recommend a target of at least three lines of ET conditional on patient’s clinical benefit (10). However, among the patients who received palliative ET in our study, the majority (55.8%) received only one line of ET, and the minority (18.9%) reached three lines of ET. Besides, the treatment duration significantly decreased from the first line onwards. A retrospective study to describe treatment patterns among postmenopausal HR+ metastatic breast cancer (MBC) patients in United States showed that the median treatment duration of ET was 11.6 months in the first line and fell to 4.9 months in the subsequent lines, and fewer than 10% of patients received three or more lines of ET before initiating CT (35). The reason for the low utilization of ET for ABC, especially dropping remarkably in the second- and third-lines, was probably because physicians expect further lines of ET to lack effectiveness due to the development of endocrine resistance eventually (35). Alternatively, patients may rapidly develop progressive disease such as life-threatening visceral metastases after the first-line treatment, making them potential candidates for chemotherapy. This might be the reason for the difficulties in achieving guideline-recommended lines of ET in real-world clinical practice. However, these speculations extend beyond the

![FIGURE 2](image-url) | Endocrine regimens use by line for HR+ ABC patients. SERMs, selective estrogen receptor modulators; AIs, aromatase inhibitors; OFS, ovarian function suppression; mTOR, mammalian target of rapamycin.
current study, and the relevant data regarding physicians' motivations for therapy transformation were not collected. Further research is needed to discuss whether the failure to reach three or more lines of ET could have an impact on OS.

As for ET regimens, we found that the majority of patients received AI monotherapy as total lines of ET; in contrast, patients were less likely to receive everolimus in combination with AIs for the ET regimens of ABC. Over the recent decades, the third-generation AIs such as letrozole, anastrozole, and exemestane have been consistently proven to be superior to tamoxifen both in advanced and in early breast cancer (36). Following AIs, fulvestrant was the next endocrine therapy to be launched in 2010 in China. The FALCON study demonstrated favorable progression-free survival (PFS) in the fulvestrant versus anastrozole (37), which has led to approvals for fulvestrant being licensed as first-line ET in postmenopausal HR+ ABC. In the real-life setting, only 138 patients (10.6% of the total ET population) were treated with fulvestrant, and a majority of them were treated in the first and second lines. Data presented here concerning the use of fulvestrant seem to be rather lower than other available data. Hartkopf et al. (15) found that 34.1% were treated with fulvestrant as single agent therapy among 958 patients with HR+ HER2-MBC in German. This diversity probably resulted from the relatively higher price of fulvestrant and limitation of the health insurance.

In addition to the guidelines for ABC, country-specific differences in accessibility may influence the treatment regimen introduced to individualized therapeutics. It was the unprecedented data about the use of everolimus after the approval in China in 2013. Only 3.5% of patients received everolimus combined therapy for the palliative ET, which may be due to the shorter time to market; thus some physicians may not be better educated on the benefits and usages of this drug. The selection of advanced endocrine drugs also includes SERMs, progestins, and so on. Considering the accessibility to drugs in clinical practice in China, although lacking of evidence of large-scale clinical RCTs, it can be used depending on the comprehensive situation of patients.

On the basis of current data, ET agents with the addition of OFS are the recommended option for first-line treatment of premenopausal HR+ advanced women. Due to the lack of updated menstrual status data, we cannot figure out the exact proportion of premenopausal patients using OFS. However, previous literature reported that the median age at natural menopause was 50 years based on 13,406 postmenopausal women in China (38). Therefore, we decided to undertake subgroup analyses of ET regimens taking into account the age as a reference. We found that higher rate of patients aged ≤50 years received OFS combination treatment than >50 patients (32.3 vs 3.2%). And there are 37.7% of patients received OFS combination therapy in the first line while 30.8 and 22.9% in the second and third lines for patients aged ≤50 years. However, among premenopausal women in the US, OFS combination therapy was used as first-line therapy in 15.9% patients, 47.8% in the second line and 27.7% in the third line for patients with HR+HER2-ABC (39).

Lack of access to new drugs and drug reimbursement policies in China also limits systemic treatment options for advanced disease. Our findings will provide reference for anti-tumor novel drug research and development, CFDA reform, and continuing medical education of doctors. We were pleased to notice that with the reform of CFDA and health care policies, China has accelerated the approval of new drugs, and the availability of new drugs has significantly improved (40). However, in the context of the presented period and healthcare policy, the group of novel agents including CDK4/6 inhibitors, PI3K inhibitors, and other new drugs have not been used in clinical practice. We hope that these situations will be improved in the upcoming epidemiological survey.

There were some limitations to our study. First, given the retrospective nature of observational study, data may be more likely to be missing or have errors compared with prospectively collected data. For example, missing data that could affect treatment decisions, such as updated menstrual status, could bias the perception of endocrine regimen selection. Second, the data in this study highly depended on the medical record of inpatients, and we did not include the outpatients which may lead to lower proportion of ET usage since a number of patients received ET in the outpatient department. Third, not only age, geographic regions, and tumor characteristics but also performance status, laboratory results, and preferences of patient and doctor are taken into consideration in making clinical treatment decisions. These factors were not accounted for in this study. Additionally, due to the very nature of our study design, survival information of this cohort was unavailable in this retrospective, observational, epidemiological study for prognostic evaluation. Further studies are required to assess the impact of treatment lines and ET regimens on survival outcomes. Finally, data were not available within this study to fully define the patient population that may be eligible for chemotherapy according to clinical guidelines (i.e., with rapidly progressive disease or proven endocrine resistance). Therefore conclusions about guideline-adherent therapy decisions were not possible in this study.

Our realistic picture of daily practice offers a good overview of the management of HR+ ABC, such as the choice of palliative treatment and drug selection of ET. To our knowledge, this is the first nation-wide study to identify ET practice patterns for HR+ ABC in China which may provide reference for investigators worldwide and multinational pharmaceutical companies. The results generated from a relatively large patient population could give valuable insight into the actual treatment delivered to the HR+ ABC patients. Previous studies have found that breast cancer characteristics in China displayed distinct features from the USA, including significant younger onset age and higher stage (41) which may influence the choice of treatment in routine practice. Our epidemiological data demonstrated that there are notable differences in physician prescription preferences and accessibility to new drugs of ABC between China and the West, which revealed that China possesses great potential for anti-tumor pharmaceutical market including ET agents and molecular-targeting drugs in combination with ET. This may provide important insight into the strategic layout and market decisions and positioning of new drug research and development for transnational pharmaceutical enterprises.
Expert Commentary on Management of ABC in China

- Improve the health care system and increase financial support to reduce out-of-pocket medical expenses.
- Increase public awareness and breast cancer screening rate to prevent stage IV disease.
- Accelerate approval of new drugs and improve quality control of generic drugs.
- Improve availability and quality of anticancer therapies for advanced breast cancer.
- Enhance the quality of surgery, radiation, essential medicines, and clinical trials to improve the disease free survival (DFS).
- Expand training of physicians and promote international collaboration on multicenter clinical trials of drugs.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

This study was approved by the Ethics Committee of Cancer Institution and Hospital, Chinese Academy of Medical Sciences. Patient consent for this study was not required as there were no anticipated risks to the enrolled patients. All data included in this analysis were in aggregate, de-identified information.

REFERENCES

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA: Cancer J Clin (2016) 66(2):115–32. doi: 10.3322/ caac.213338

2. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (London Engl) (2019) 39(1):22. doi: 10.1186/s40880-019-0368-6

3. Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, et al. Breast cancer metastasis: challenges and opportunities. Cancer Res (2009) 69(12):4951–3. doi: 10.1158/0008-5472.CAn-09-0099

4. Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012. Curr Med Res Opin (2014) 30(8):1537–45. doi: 10.1185/03007959.2014.908829

5. El Saghir NS, Tlayli A, Hatoum HA, Nachev Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol (2011) 80(3):433–49. doi: 10.1016/j.critrevonc.2011.01.010

6. Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, et al. Measures of outcome in metastatic breast cancer: insights from a real-world scenario. Oncologist (2014) 19(6):608–15. doi: 10.1634/theoncologist.2014-0002

7. Waks AG, Winer EP. Breast Cancer Treatment: A Review. Jama (2019) 321(3):288–300. doi: 10.1001/jama.2018.19323

8. Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet (London Engl) (2017) 389(10087):2403–14. doi: 10.1016/s0140-6736(16)32419-9

AUTHOR CONTRIBUTIONS

BX, JW, JF, and YQ were involved in the study design. All authors were responsible for the data collection and case confirmation. YW did the statistical analyses and drafted the manuscript. YH, BX, and JW modified and revised the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Investigator-initiated program of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CH-BC-045).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2020.599604/full#supplementary-material
17. Chen MT, Sun HF, Zhao Y, Fu WY, Yang LP, Gao SP, et al. Comparison of age of diagnosis of breast cancer in china: almost 10 years earlier than in the United States and the European union. *Asian Pac J Cancer Prev* APJCP (2014) 15(22):10021–5. doi: 10.7314/apjcp.2014.15.22.10021

18. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. *J Clin Oncol Off J Am Soc Clin Oncol* (2009) 27(21):3445–51. doi: 10.1200/jco.2008.19.2419

19. Svahn TH, Niland JC, Carlson RW, Hughes ME, Ottesen RA, Theriault RL, et al. Predictors and temporal trends of adjuvant aromatase inhibitor use in breast cancer. *J Natl Compr Cancer Netw* JNCCN (2009) 7(2):115–21. doi: 10.6004/jnccn.2009.0011

20. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol* (2004) 22(16):3309–15. doi: 10.1200/jco.2004.11.064

21. Harlan LC, Clegg LX, Abrams J, Stevens JL, Ballard-Barbash R. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. *J Clin Oncol Off J Am Soc Clin Oncol* (2006) 24(6):872–7. doi: 10.1200/jco.2005.03.5840

22. Cuncins-Hearn AV, Boul J, Babinet W, Zorbas H, Villanueva E, Evans A, et al. National breast cancer audit: overview of invasive breast cancer management. *ANZ J Surg* (2006) 76(8):745–50. doi: 10.1111/j.1445-2197.2006.03846.x

23. Andre F, Neven P, Marinsek N, Zhang J, Baladi J-F, Degun R, et al. Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. *Curr Med Res Opin* (2014) 30(6):1007–16. doi: 10.1185/03007995.2014.887002

24. Lobbezoo DJA, van Kampen RJW, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. In real life, one-quarter of patients with hormone-receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. *Ann Oncol* (2016) 27(2):256–62. doi: 10.1093/annonc/mdv544

25. Gao S, Barber B, Schabert V, Ferrufino C. Tumor hormone/HER2 receptor status and pharmacologic treatment of metastatic breast cancer in Western Europe. *Curr Med Res Opin* (2012) 28(7):1111–8. doi: 10.1185/03007995.2012.694364

26. Lux MP, Bauer CM, Loehberg CR, Schrauder MG, Bani MB, et al. Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. *Breast Cancer Res Treat* (2013) 139(2):429–40. doi: 10.1007/s10549-013-2557-3

27. Swain SM, Kim S-B, Cortès J, Ro J, Semiglavzov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol* (2013) 14(6):461–71. doi: 10.1016/S1470-2045(13)70130-X

28. Johnston S, Pippen Jr., Pivot X, Lichinifter M, Sadeghi S, Dieras V, et al. Laptatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol Off J Am Soc Clin Oncol* (2009) 27(33):5538–46. doi: 10.1200/jco.2009.23.3734

29. Niikura N, Liu J, Hayashi N, Palla SL, Tokuda Y, Hortobagyi GN, et al. Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. *Oncologist* (2011) 16(2):155–64. doi: 10.1634/theoncologist.2010-0350

30. Guerraz A, Fanotto V, Bonotto M, Bolzonello M, Minisini AM, Fosola G, et al. Pattern of metastasis and outcome in patients with breast cancer. *Clin Exp Metastasis* (2015) 32(2):125–33. doi: 10.1007/s10585-015-9697-2

31. Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, et al. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. *J Natl Compr Cancer Netw JNCCN* (2019) 17(2):118–26. doi: 10.6004/jnccn.2019.0009

32. Watanabe J, Hayashi T, Tadokoro Y, Nishimura S, Takahashi K. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. *Breast Cancer Res Treat* (2017) 166(3):911–7. doi: 10.1007/s10549-017-4478-z

33. Bruincky AM, Dickler MN. Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. *Oncologist* (2018) 23(5):528–39. doi: 10.1634/theoncologist.2017-0423

34. Rani A, Stebbing J, Giamas G, Murphy J. Endocrine Resistant Hormone Receptor Positive Breast Cancer-From Mechanism to Therapy. *Front Endocrinol* (2019) 10:245. doi: 10.3389/fendo.2019.00245

35. Macalard AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, et al. Treatment patterns and duration in post-menopausal women with HR+HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). *Carr Med Res Opin* (2015) 31(2):263–73. doi: 10.1185/03007995.2014.980885

36. Reinert T, Debiasi M, Bines J, Barrios CH. Trends in progression-free survival (PFS) and time to progression (TTP) over time within first-line aromatase inhibitors trials in hormone-receptor-positive advanced breast cancer. *Breast Cancer Res Treat* (2018) 168(2):457–65. doi: 10.1007/s10549-017-4593-x

37. Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. *Lancet (London England)* (2016) 388(10063):2997–3005. doi: 10.1016/s0140-6736(16)32839-3

38. Song L, Shen L, Li H, Liu B, Zhang X, Zhang L, et al. Age at natural menopause and hypertension among middle-aged and older Chinese women. *J Hypertension* (2018) 36(3):594–600. doi: 10.1097/HJH.0000000000001585

39. Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guerin A, Niravath P, et al. Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer. *Adv Ther* (2018) 35(9):1356–67. doi: 10.1007/s12325-018-0764-3

40. Zhou Q, Chen X-Y, Yang Z-M, Wu Y-L. The changing landscape of clinical trial and approval processes in China. *Nat Rev Clin Oncol* (2017) 14(9):577–83. doi: 10.1038/nrclinonc.2017.10

41. Chen C, Sun S, Yuan JP, Wang YH, Cao TZ, Zheng HM, et al. Characteristics of breast cancer in Central China, literature review and comparison with USA. *Breast (Edinburgh Scotland)* (2016) 30:208–13. doi: 10.1016/j.breast.2016.01.004

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.